The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …

Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable
hematological malignancy that affects the myeloid cell progenies and challenges patients of …

Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell
therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell …

The immune system evolved to distinguish non-self from self to protect the organism. As
cancer is derived from our own cells, immune responses to dysregulated cell growth present …

For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …

The absence of cancer-restricted surface markers is a major impediment to antigen-specific
immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the …

Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involves
administration to the cancer-bearing host of immune cells with direct anticancer activity. ACT …

In spite of the recent approval of new promising targeted therapies, the clinical outcome of
patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for …

The prognosis of patients with acute myeloid leukemia (AML) remains dismal, highlighting
the need for novel innovative treatment strategies. The application of chimeric antigen …

Genetically engineered T cells are powerful new medicines, offering hope for curative
responses in patients with cancer. Chimeric antigen receptor (CAR) T cells were recently …